Eton Pharmaceuticals, Inc. (ETON) News
Follow Eton Pharmaceuticals, Inc. (ETON) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 29 public stories across 15 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Eton Pharmaceuticals Raises Full-Year Outlook After Third-Quarter Revenue More Than Doubles
Eton Pharmaceuticals raised its outlook for the year after third-quarter revenue more than doubled. The stock rose 12% to $52.59 on Friday.
EQUITY | Nov 06, 2026, 03:18 PM UTC
M
Eton Pharmaceuticals Reports Quarterly Results for Period Ended September 30
EQUITY | Nov 05, 2026, 11:28 PM UTC
M
Eton Pharmaceuticals Raises 2026 Revenue Guidance After Third-Quarter Results
Eton reported third-quarter revenue of $57.9 million versus $22.5 million a year earlier, GAAP diluted EPS of $1.06 and an Adjusted EBITDA margin of 49%. It raised 2026 revenue guidance to more than $175 million and marg
EARNINGS | Nov 05, 2026, 10:33 PM UTC
M
Eton Pharmaceuticals Reports Third-Quarter 2026 Financial Results
Eton reported results for the quarter ended September 30, 2026.
EQUITY | Nov 05, 2026, 09:37 PM UTC
M
Eton Raises 2026 Revenue Guidance Above $175M
Eton raised its 2026 revenue guidance to more than $175 million from more than $145 million and its adjusted EBITDA margin guidance to at least 40% from at least 35%. Q3 revenue was $57.9 million, up 158% from $22.5 mill
EARNINGS | Nov 05, 2026, 09:09 PM UTC
M
Eton Pharmaceuticals to Report Third-Quarter Results
Eton Pharmaceuticals says it will report third-quarter financial results.
EQUITY | Oct 29, 2026, 10:58 AM UTC
M
Eton Licenses U.S. Rights to LIBERVANT for $10M Upfront
Eton Pharmaceuticals entered two agreements with Aquestive Therapeutics for exclusive U.S. commercialization rights to LIBERVANT, a diazepam buccal film for epilepsy, subject to FDA approvals. The deal includes $10 milli
EQUITY | Oct 14, 2026, 11:23 AM UTC
L
Eton and Aquestive Announce U.S. Licensing Agreement for LIBERVANT
Eton Pharmaceuticals and Aquestive Therapeutics announced an exclusive U.S. licensing agreement for LIBERVANT (diazepam) buccal film.
EQUITY | Oct 14, 2026, 10:50 AM UTC
L
Eton Pharmaceuticals launches U.S. commercial availability of IMPAVIDO with patient support
Eton Pharmaceuticals launched U.S. commercial availability of IMPAVIDO (miltefosine) capsules and integrated Eton Cares patient support including $0 co-pay for eligible commercially insured patients.Key Highlights:Origin
REGULATION | Sep 28, 2026, 11:24 AM UTC
L
Weekly Recap: IMPAVIDO relaunch and leishmaniasis label with safety notes
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has relaunched IMPAVIDO (miltefosine) in the U.S., distributing via Eton Cares, specialty distributors and hospital consignment to broaden rare—disease access while labeling it fo
NEWS | Sep 28, 2026, 11:07 AM UTC
L
Eton Pharmaceuticals, Inc (ETON) Relaunches IMPAVIDO in U.S.
Eton Pharmaceuticals announced U.S. commercial availability of IMPAVIDO (miltefosine) capsules, adding the drug to its rare disease commercial infrastructure and support program.Material DetailsContext by AI AnalystThis
NEWS | Sep 28, 2026, 10:51 AM UTC
L
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) NASDAQ:ETON, an innovative pharmaceutical company focused on developing and commercializing treatments for rare dise
NEWS | Sep 28, 2026, 10:51 AM UTC
H
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
The biotech sector is heading into the third-quarter earnings season with a tug-of-war between higher interest rates and an unusually heavy pipeline of company-specific catalysts. The SPDR S&P Biotech ETF (NYSE: XBI ) is
LIVE | Sep 25, 2026, 08:19 PM UTC
L
ETON director sold shares worth over $2.9M
Eton Pharmaceuticals director sold shares worth over $2.9M, according to TradingView News.
EQUITY | Aug 28, 2026, 09:02 PM UTC
L
Cramer praises Smithfield, Eton and IES, pans BW
On CNBC’s Mad Money Lightning Round, Jim Cramer called Smithfield Foods inexpensive, said Eton Pharmaceuticals has been a winner and backed IES Holdings, while criticizing Babcock & Wilcox.
EARNINGS | Aug 27, 2026, 11:38 AM UTC
L
Eton Pharmaceuticals to participate in 2026 Wells Fargo healthcare conference
Eton Pharmaceuticals said it will participate at the 2026 Wells Fargo Healthcare Conference.
EQUITY | Aug 27, 2026, 10:57 AM UTC
L
Dow drops about 108 points as Fear & Greed stays in Greed
The Dow fell around 108 points to 53,732.41 on Friday, while the CNN Fear & Greed index declined but remained in the “Greed” zone; U.S. retail sales and consumer sentiment also weakened.
EARNINGS | Aug 17, 2026, 06:41 AM UTC
L
University of Michigan sentiment falls to 51 in early August
The University of Michigan's consumer sentiment index declined to 51 in early August from 55.2 in the previous month, missing market estimates of 54.5.
EARNINGS | Aug 14, 2026, 04:02 PM UTC
L
Heartflow, Eton, Nu Holdings rise on earnings and guidance
Heartflow shares jump after quarterly adjusted EPS beats estimates while revenue misses; Eton Pharmaceuticals and Nu Holdings also climb after better-than-expected quarterly results, and Eton issues FY26 revenue guidance
EARNINGS | Aug 14, 2026, 01:55 PM UTC
L
Eton Pharmaceuticals jumps on Q2 results, FY26 revenue guidance
Eton Pharmaceuticals shares trade higher after the company reported better-than-expected Q2 results and issued FY26 revenue guidance above estimates, with HC Wainwright keeping a Buy rating and raising its price target f
EARNINGS | Aug 14, 2026, 11:57 AM UTC
L
Eton Pharmaceuticals rises after Q2 beat and FY26 revenue guidance
Eton Pharmaceuticals said second-quarter earnings were 43 cents a share versus the 10-cent consensus and sales were $37.568 million versus $27.119 million, while FY26 revenue guidance came in above estimates.
EARNINGS | Aug 14, 2026, 08:37 AM UTC
L
Eton Pharmaceuticals reports record Q2 revenue, raises 2026 guidance
Eton Pharmaceuticals reports second-quarter revenue of $37.6 million, up 99% year over year, and raises 2026 revenue guidance to exceed $145 million while lifting its adjusted EBITDA margin outlook to above 35%.
EARNINGS | Aug 13, 2026, 09:44 PM UTC
L
Eton Pharmaceuticals shares rise on Q2 results, FY26 revenue guidance
Eton Pharmaceuticals is up after reporting better-than-expected Q2 financial results and issuing FY26 revenue guidance above estimates, according to Alpaca Benzinga Live.
EARNINGS | Aug 13, 2026, 08:22 PM UTC
L
Eton Pharmaceuticals reports Q2 2026 financial results
Eton Pharmaceuticals (ETON) reports its second quarter 2026 financial results.
EARNINGS | Aug 13, 2026, 08:10 PM UTC
H
Eton Pharmaceuticals Acquires US Rights To ASN-001
Eton expands infantile hemangioma franchise
EQUITY | Aug 05, 2026, 10:50 AM UTC
L
ETON - Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
ETON - Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
EARNINGS | Aug 03, 2026, 10:50 AM UTC
L
ETON - Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Soluti
ETON - Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
EQUITY | Jul 29, 2026, 10:50 AM UTC
L
Apple upgraded, Brinker initiated: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: HSBC upgraded Apple (AAPL) to Buy
EQUITY | Jul 17, 2026, 01:43 PM UTC
L
ETON Initiated Buy and $60 PT @ Canaccord
ETON Initiated Buy and $60 PT @ Canaccord
EQUITY | Jul 17, 2026, 12:31 PM UTC